Morgan Stanley reissued their equal weight rating on shares of Olink Holding AB (publ) (NASDAQ:OLK – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $26.00 price target on the stock.
Separately, Canaccord Genuity Group reissued a hold rating and set a $26.00 target price on shares of Olink Holding AB (publ) in a report on Tuesday.
Get Our Latest Report on Olink Holding AB (publ)
Olink Holding AB (publ) Trading Down 0.4 %
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. TD Asset Management Inc raised its holdings in Olink Holding AB (publ) by 73.7% during the third quarter. TD Asset Management Inc now owns 403,924 shares of the company’s stock worth $5,958,000 after buying an additional 171,395 shares during the last quarter. Trexquant Investment LP raised its holdings in Olink Holding AB (publ) by 23.0% during the third quarter. Trexquant Investment LP now owns 33,156 shares of the company’s stock worth $489,000 after buying an additional 6,193 shares during the last quarter. US Bancorp DE raised its holdings in Olink Holding AB (publ) by 874.4% during the second quarter. US Bancorp DE now owns 9,666 shares of the company’s stock worth $181,000 after buying an additional 8,674 shares during the last quarter. Rock Springs Capital Management LP raised its holdings in shares of Olink Holding AB (publ) by 1.4% in the third quarter. Rock Springs Capital Management LP now owns 1,676,500 shares of the company’s stock valued at $24,728,000 after purchasing an additional 22,500 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Olink Holding AB (publ) by 3.7% in the third quarter. New York State Common Retirement Fund now owns 67,166 shares of the company’s stock valued at $991,000 after purchasing an additional 2,368 shares during the last quarter. 30.19% of the stock is owned by institutional investors.
About Olink Holding AB (publ)
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.
Further Reading
- Five stocks we like better than Olink Holding AB (publ)
- 10 Best Airline Stocks to Buy
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Breakout Stocks: What They Are and How to Identify Them
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What Are the U.K. Market Holidays? How to Invest and Trade
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Olink Holding AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olink Holding AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.